Assignee
ASCENTAWITS PHARMACEUTICALS LTD
CN·1 granted patent·19 pending applications·0 citations·filing 2019–2023
Top patents by PatentIndex Score
20 records- 0154US2025295677A1Method for treating cancer by using th-302 alone or in combination with parp inhibitorASCENTAWITS PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0251US2024425461A1Preparation process of intermediate, synthesis process of amino imidazole carboxylate ester and hplc purity measure methodASCENTAWITS PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0349US2023339991A1Hypoxia-activated dna alkylating agent and medical use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 0449US2025011348A1Synthesis Process of X-IPM, Stable Crystal Form and Application ThereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0549US2025186468A1Method for treating patient with brca-mutated cancerASCENTAWITS PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0646US2024425462A1Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl ImidazoleASCENTAWITS PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0746US2025387419A1Parp inhibitor-resistant patient treated with th-302ASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 0846US2024401144A2Primer-probe composition, kit, and detection methodASCENTAWITS PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 0946US2024366640A1Lyophilized formulation solution and lyophilized formulation, and method and use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1046US2023026163A1Anticancer compound and medical use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1142US2025281514A1Treatment of cancer patients having kras mutationsASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1241US2024142453A1Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1340US2025304606A2A deuterated compound, and preparation method and use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1440US2024368209A1Gemcitabine anticancer derivative and anticancer pharmaceutical useASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1536US2022251021A1Akr1c3 inhibitor and medical useASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1635US12595275B2Fluorine-containing compound and anti-cancer medical use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Granted Apr 7, 2026·0 cites·17 claims
- 1734US2022387345A1Anti-cancer compounds acting as non-pgp substrateASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1831US2023017359A1Method for associating with expression level of akr1c3 enzyme via content of prostaglandin, and use of screening for drug administrationASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1930US2022395464A1Orally administered solid dosage form drugASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 2026US2021283151A1Use of compound in drug for preventing, treating, or alleviating painASCENTAWITS PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ASCENTAWITS PHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →